Ireland· IE-PA-PA0822/123/002
Depo-Medrone 40mg/ml with Lidocaine 10mg/ml Suspension for Injection, 2ml vial
A methylprednisolone product containing methylprednisolone acetate + lidocaine hydrochloride, registered in Ireland by Pfizer Healthcare Ireland Unlimited Company. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Methylprednisolone is registered in 15 of 19 countries.
Countries holding a registration under ATC H02AB04 (methylprednisolone), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Methylprednisolone · ATC H02AB04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of methylprednisolone costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), the median price runs from $0.13 in Italy to $0.85 in Switzerland — a ×6.4 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Methylprednisolone · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.85
- IT Italy$0.13
The record
At a glance
HPRA (Ireland)- Active substance
- Methylprednisolone acetate + Lidocaine hydrochloride
- Manufacturer
- Pfizer Healthcare Ireland Unlimited Company
- Country
- Ireland (IE)
- ATC code
- H02AB04
- ATC class
- Methylprednisolone
- Defined daily dose
- 7.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0822/123/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
802 interactions on record for methylprednisolone.
Graded by severity as the source publishes them — 84 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Methylprednisolone · interactions on record
802 records
- 84 severe
- 367 moderate
- 43 minor
- 288 info
Most severe, free to view
- LonafarnibA16AX20severe
- DesirudinB01AE01severe
- ConivaptanC03XA02severe
- Magnesium hydroxideA02AA04moderate
20 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Methylprednisolone in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomDepo-Medrone with Lidocaine suspension for injection 1ml vialsDE Pharmaceuticals
- SwitzerlandDepo Medrol Lidocain
- SwedenDepo-Medrol cum lidocain 40 mg/ml+10 mg/ml Injektionsvätska, suspensionPfizer AB
- FinlandDepo-Medrol Cum LidocainPfizer Oy
- CanadaDEPO-MEDROL WITH LIDOCAINEPFIZER CANADA ULC
- NetherlandsDepo Medrol + Lidocaïne, suspensie voor injectiePfizer B.V.
- PolandDepo-Medrol z LidokainąPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Belgium · Depo-Medrol + Lidocain, Depo-Medrol + Lidocaïne
- Finland · Depo-Medrol Cum Lidocain
- United Kingdom (Northern Ireland) · Depo-Medrone With Lidocaine
- Italy · Lidodepomedrol
- Luxembourg · Depo-Medrol + Lidocain, Depo-Medrol + Lidocaïne
- Netherlands · Depo-Medrol + Lidocaïne
- Poland · Depo-Medrol Z Lidokainą
- Portugal · Depo-Medrol Com Lidocaína
- Sweden · Depo-Medrol Cum Lidocain
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/13a49a2c-a421-46c3-a518-d239d527e902 GET /v1/drugs/13a49a2c-a421-46c3-a518-d239d527e902?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Suspension for injection",
"routes": [
"Not Currently Available"
],
"source": "hpra",
"atc_all": [
"H02AB",
"H02AB04"
],
"strength": null,
"pa_number": "PA0822/123/002",
"substances": [
"Methylprednisolone acetate",
"Lidocaine hydrochloride"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "02/03/1981",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about methylprednisolone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.